Microsoft: A Critical Point in Valuation Momentum
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
Cassava Sciences (SAVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: May 24, 2025 (15:40)
Sector: HealthcareThe share price of Cassava Sciences, Inc. (SAVA) now
News Impact Analyzer
Full report
This Week
|
Na | Impact: Na | News: Na |
Previous Week
|
Na | Impact: Na | News: Na |
Two Weeks Ago
|
Bearish | Impact: 5 | News: 1 |
Three Weeks Ago
|
Na | Impact: Na | News: Na |
Analysts predictions
Full report
This Week
|
Bearish | Opinions: 1 |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Bearish | Opinions: 1 |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important SAVA news

Cassava Sciences Reports Q1 Loss Amid Clinical Challenges


Cassava Sciences CMO Retirement Signals Leadership Shifts


Tuesday’s Stock Picks: GME, TSLA, SAVA and CCI in Focus

Historical and forecast chart of Cassava Sciences stock
The chart below shows the historical price of Cassava Sciences stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Cassava Sciences stock price can be found in the table below.
Long-term forecasts by years.
Cassava Sciences, Inc. Analysts predictions review

Cassava Sciences (SAVA) faces significant headwinds, driven by concerns over its flagship Alzheimer’s drug, Simufilam, and regulatory hurdles. Critical challenges include data validation issues, regulatory scrutiny, and a lack of pipeline diversification, all of which heighten operational and investment risks. The company’s recent pivot to Tuberous Sclerosis Complex (TSC) epilepsy lacks competitive differentiation, raising doubts about strategic focus and long-term revenue sustainability. Additionally, cash flow pressures and potential dilution amplify downside risk. Investor sentiment remains fragile, with the stock highly dependent on near-term clinical data updates, leaving it prone to volatility.

Cassava Sciences: Uncertainty in Alzheimer's Drug Results May Limit Upside Despite Developments

The potential for Cassava Sciences to make breakthroughs in Alzheimer's treatments remains a crucial aspect for investors. The company’s novel therapeutic approach, while promising in its early stages, still faces significant scientific and regulatory hurdles. These uncertainties add a layer of skepticism about the potential for near-term success, despite recent developments in their pipeline.
Uncertainty Looms Over Data Validation and Market Adoption
Data validation challenges surrounding Cassava's Alzheimer's drug trials have raised concerns among the investing community. This has left the company at risk of investor backlash and potential valuation compression if results fall short of high expectations.
Investor sentiment is likely to remain tied to near-term clinical data updates, making the stock prone to volatility. Additionally, new developments, while encouraging, do not yet provide sufficient clarity to materially shift the risk-reward equation in a positive manner.

Cassava Sciences’ TSC Epilepsy Strategy Faces Hurdles in Driving Sustainable Value

The author highlights that Cassava Sciences' pivot toward Tuberous Sclerosis Complex (TSC) epilepsy, while potentially addressing an unmet need, lacks a clear competitive advantage and robust clinical data. This uncertainty weighs on investor confidence as it suggests a speculative use of resources rather than a well-defined growth trajectory.
Challenges in Strategic Execution
The addressed cost-effectiveness of this pivot is questioned, given the high costs typically associated with developing treatments for rare diseases like TSC. Strategic implementation without proven differentiation may dilute resource allocation and risk value erosion.
Lastly, long-term shareholder value is scrutinized due to doubts about sustained revenue streams post-commercialization. The absence of a clear market advantage or partnerships could limit scalability, restricting the stock's upside potential.

Cassava Sciences Faces Challenges with Simufilam Amid Mounting Investor Concerns

Cassava Sciences (SAVA) is currently grappling with significant challenges surrounding its flagship drug candidate, Simufilam. The reported issues center on both the drug's efficacy and ongoing regulatory scrutiny, which have raised doubts about its commercial viability. These obstacles pose a serious threat to future revenue projections and investor sentiment.
The author highlights concerns about the company’s regulatory hurdles, particularly involving the FDA. Any lack of clarity or unfavorable outcomes in the regulatory process could magnify uncertainty around the drug's approval timeline, thereby pressuring the stock further in the near term.
Financial Stability and Pipeline Dependency
Another critical factor is SAVA’s heavy reliance on Simufilam as its primary asset. With little diversification in its pipeline, the company faces heightened operational risk, leaving the stock vulnerable to any setbacks in clinical trials or commercial milestones.
Additionally, Cassava's cash runway was discussed as a pressing concern. Depleting cash reserves and the potential for a need to raise additional capital are likely to result in shareholder dilution, which could weigh on the stock significantly.
The author underscores the significant challenges facing Cassava Sciences in its development of Simufilam, a drug targeting Alzheimer’s disease, primarily due to skepticism surrounding its clinical efficacy. This skepticism emanates from inconclusive or controversial data related to the drug’s underlying mechanisms, a central factor that may weigh heavily on investor confidence and near-term stock performance.
Further, they highlight the consequences of regulatory scrutiny, particularly in the form of delays and rigorous oversight from entities such as the FDA. This regulatory pressure introduces heightened uncertainty, prolonging timelines and increasing development costs, which could amplify the stock's downside risks.
Market Position and Prospects
The article emphasizes Cassava’s reliance on Simufilam as its primary revenue driver, suggesting that failure or delays in its approval could pose significant threats to the company's financial stability. Given the absence of commercialized products, Cassava’s dependency on external funding and partnerships could become more precarious without positive clinical updates.
Lastly, the REFOCUS program, meant to bolster Simufilam’s development, is viewed by the author as unlikely to resolve the core concerns about the drug's effectiveness. While this initiative appears to be a step in the right direction, it lacks the compelling evidence needed to turn sentiment around, potentially leaving the stock in a vulnerable position.
Recent developments regarding Cassava Sciences highlight significant regulatory and scientific concerns that directly impact investor sentiment. Allegations of data manipulation in the company's drug trials, coupled with ongoing investigations by the SEC, raise questions about management credibility and ethical compliance, potentially hampering investor confidence in the short to medium term.
Another critical factor is the lack of conclusive clinical evidence supporting the efficacy of Cassava's lead drug candidate, Simufilam, for Alzheimer’s disease. Given the highly competitive nature of the biotech sector and the scrutiny placed on late-stage trials, any perceived shortcomings in data can exacerbate market skepticism, affecting stock valuation.
Key Operational and Financial Considerations
The company's financial position also poses potential risks, as reliance on external funding could increase if regulatory delays arise. Investors may view this as a dilution risk, further pressuring the share price until clinical milestones are achieved or regulatory clarity is provided.
Conversely, any favorable resolution of investigations or positive clinical outcomes could act as significant catalysts for recovery. However, such a scenario remains speculative, contingent on factors outside the company's immediate control.
Comprehensive Analysis of Cassava Sciences (SAVA) Stock Market Performance
Our multifaceted analysis of Cassava Sciences's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Cassava Sciences stock?
- When should I record a loss on Cassava Sciences stock?
- What are analysts' forecasts for Cassava Sciences stock?
- What is the future of Cassava Sciences stock?
We forecast Cassava Sciences stock performance using neural networks based on historical data on Cassava Sciences stocks.
Cassava Sciences uses drugs using proprietary technologies. The company offers safer and more effective pain relievers, especially in the field of opioid pain relievers.
Cassava Sciences, Inc. News influencing stock rates

As of now, Panda has combed through 1 news items directly related to SAVA from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 1 display bearish tendencies, and 0 events are neutral.
Based on an analysis of the most crucial news from the last 30 days affecting SAVA stocks, it's clear that bearish sentiments are completely overshadowing bullish ones. The impact of negative news is more than five times dominant over positive developments.
The news analyzed fell within the period from May 08, 2025, to May 08, 2025.
Cassava Sciences Drops Alzheimer’s Drug After Failure, Shares Tank


Cassava Sciences Posts Narrower Q4 Loss, Maintains Strong Cash Position


Cassava Sciences Soars on Exclusive Yale IP Deal


Cassava Axes Phase 3 Alzheimer's Trial for Simufilam Amid Strategic Pivot


Cassava Sciences Cuts Workforce Amid Cash Conservation Efforts


Cassava Sciences daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May 26 | 2.04 | 2.01 | 2.06 | 2.27 |
May 27 | 2.06 | 2.02 | 2.09 | 3.68 |
May 28 | 2.06 | 2.03 | 2.07 | 2.19 |
May 29 | 2.03 | 1.99 | 2.05 | 3.47 |
May 30 | 2.08 | 2.04 | 2.14 | 4.97 |
May 31 | 2.16 | 2.12 | 2.23 | 5.15 |
Jun 01 | 2.14 | 2.07 | 2.17 | 4.57 |
Jun 02 | 2.16 | 2.12 | 2.18 | 2.81 |
Jun 03 | 2.12 | 2.08 | 2.17 | 4.28 |
Jun 04 | 2.04 | 2.00 | 2.06 | 2.77 |
Jun 05 | 1.99 | 1.92 | 2.00 | 4.00 |
Jun 06 | 2.03 | 1.97 | 2.05 | 3.96 |
Jun 07 | 2.01 | 1.95 | 2.06 | 5.74 |
Jun 08 | 2.01 | 1.99 | 2.05 | 2.94 |
Jun 09 | 2.08 | 2.06 | 2.11 | 2.67 |
Jun 10 | 2.15 | 2.11 | 2.17 | 2.64 |
Jun 11 | 2.16 | 2.13 | 2.22 | 4.43 |
Jun 12 | 2.25 | 2.22 | 2.28 | 2.83 |
Jun 13 | 2.16 | 2.14 | 2.21 | 3.27 |
Jun 14 | 2.16 | 2.10 | 2.21 | 5.64 |
Jun 15 | 2.15 | 2.10 | 2.22 | 5.87 |
Jun 16 | 2.16 | 2.13 | 2.20 | 3.17 |
Jun 17 | 2.20 | 2.15 | 2.25 | 4.58 |
Jun 18 | 2.17 | 2.11 | 2.22 | 5.07 |
Jun 19 | 2.22 | 2.16 | 2.24 | 3.78 |
Jun 20 | 2.30 | 2.27 | 2.35 | 3.48 |
Jun 21 | 2.30 | 2.28 | 2.36 | 3.84 |
Jun 22 | 2.28 | 2.24 | 2.33 | 4.03 |
Jun 23 | 2.21 | 2.17 | 2.28 | 5.06 |
Jun 24 | 2.20 | 2.16 | 2.26 | 4.43 |
Cassava Sciences Daily Price Targets
Cassava Sciences Stock Forecast 05-26-2025.
Forecast target price for 05-26-2025: $2.04.
Negative dynamics for Cassava Sciences shares will prevail with possible volatility of 2.221%.
Pessimistic target level: 2.01
Optimistic target level: 2.06
Cassava Sciences Stock Forecast 05-27-2025.
Forecast target price for 05-27-2025: $2.06.
Positive dynamics for Cassava Sciences shares will prevail with possible volatility of 3.551%.
Pessimistic target level: 2.02
Optimistic target level: 2.09
Cassava Sciences Stock Forecast 05-28-2025.
Forecast target price for 05-28-2025: $2.06.
Negative dynamics for Cassava Sciences shares will prevail with possible volatility of 2.143%.
Pessimistic target level: 2.03
Optimistic target level: 2.07
Cassava Sciences Stock Forecast 05-29-2025.
Forecast target price for 05-29-2025: $2.03.
Negative dynamics for Cassava Sciences shares will prevail with possible volatility of 3.356%.
Pessimistic target level: 1.99
Optimistic target level: 2.05
Cassava Sciences Stock Forecast 05-30-2025.
Forecast target price for 05-30-2025: $2.08.
Positive dynamics for Cassava Sciences shares will prevail with possible volatility of 4.735%.
Pessimistic target level: 2.04
Optimistic target level: 2.14
Cassava Sciences Stock Forecast 05-31-2025.
Forecast target price for 05-31-2025: $2.16.
Positive dynamics for Cassava Sciences shares will prevail with possible volatility of 4.899%.
Pessimistic target level: 2.12
Optimistic target level: 2.23
SAVA (SAVA) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun. | 2.32 | 2.24 | 2.53 | 11.67 |
Jul. | 2.15 | 1.98 | 2.26 | 12.58 |
Aug. | 2.16 | 2.03 | 2.29 | 11.20 |
Sep. | 2.07 | 1.91 | 2.30 | 16.90 |
Oct. | 2.07 | 1.94 | 2.17 | 10.86 |
Nov. | 2.26 | 2.05 | 2.40 | 14.41 |
Dec. | 2.46 | 2.17 | 2.71 | 20.01 |
Cassava Sciences forecast for this year
Cassava Sciences Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $2.31716. Pessimistic: $2.24. Optimistic: $2.53
Cassava Sciences Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $2.1538. Pessimistic: $1.98. Optimistic: $2.26
Cassava Sciences Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $2.16349. Pessimistic: $2.03. Optimistic: $2.29
Cassava Sciences Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $2.07263. Pessimistic: $1.91. Optimistic: $2.30
Cassava Sciences Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $2.06952. Pessimistic: $1.94. Optimistic: $2.17
Cassava Sciences Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $2.25888. Pessimistic: $2.05. Optimistic: $2.40
Cassava Sciences Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $2.46218. Pessimistic: $2.17. Optimistic: $2.71
Cassava Sciences (SAVA) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 2.36 | 2.12 | 2.55 | 16.81 |
Feb | 2.28 | 2.16 | 2.40 | 10.12 |
Mar | 2.28 | 2.15 | 2.41 | 10.66 |
Apr | 2.35 | 2.26 | 2.49 | 9.21 |
May | 2.06 | 1.85 | 2.13 | 13.23 |
Jun | 2.26 | 2.13 | 2.44 | 12.77 |
Jul | 2.39 | 2.18 | 2.61 | 16.38 |
Aug | 2.61 | 2.45 | 2.81 | 12.54 |
Sep | 2.78 | 2.62 | 2.97 | 11.93 |
Oct | 3.19 | 2.97 | 3.49 | 14.84 |
Nov | 3.17 | 2.79 | 3.27 | 14.81 |
Dec | 3.50 | 3.22 | 3.90 | 17.37 |
Cassava Sciences (SAVA) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 3.36 | 3.11 | 3.66 | 15.12 |
Feb | 2.93 | 2.61 | 3.19 | 18.08 |
Mar | 2.81 | 2.68 | 2.94 | 8.74 |
Apr | 2.48 | 2.25 | 2.66 | 15.37 |
May | 2.53 | 2.40 | 2.69 | 10.61 |
Jun | 2.74 | 2.61 | 2.88 | 9.55 |
Jul | 2.99 | 2.63 | 3.30 | 20.23 |
Aug | 3.02 | 2.76 | 3.17 | 13.13 |
Sep | 3.22 | 2.97 | 3.36 | 11.61 |
Oct | 3.04 | 2.71 | 3.38 | 19.71 |
Nov | 3.11 | 2.99 | 3.46 | 13.37 |
Dec | 2.89 | 2.69 | 3.22 | 16.65 |
Cassava Sciences information and performance
7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN, TX, US
Market capitalization of the Cassava Sciences, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of SAVA shares in the company outstanding by the market price of one share.
EBITDA of Cassava Sciences is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Cassava Sciences (SAVA) stock dividend
Cassava Sciences last paid dividends on 12/13/2012. The next scheduled payment will be on 05/10/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Cassava Sciences Stock)
Should I Buy Cassava Sciences Shares in 2025 year?
Does Cassava Sciences pay dividends?
Which economic sector do Cassava Sciences's shares belong to?
Which other securities belong to the same sector as Cassava Sciences's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.